Oberweis Asset Management Inc. Has $3.55 Million Stake in Medpace Holdings Inc (MEDP)

Oberweis Asset Management Inc. decreased its holdings in shares of Medpace Holdings Inc (NASDAQ:MEDP) by 2.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 67,005 shares of the company’s stock after selling 1,875 shares during the quarter. Oberweis Asset Management Inc.’s holdings in Medpace were worth $3,547,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in MEDP. BlackRock Inc. grew its stake in shares of Medpace by 82.2% during the fourth quarter. BlackRock Inc. now owns 4,158,359 shares of the company’s stock valued at $220,103,000 after buying an additional 1,876,296 shares during the last quarter. Pendal Group Ltd grew its stake in shares of Medpace by 10,018.7% during the fourth quarter. Pendal Group Ltd now owns 1,593,387 shares of the company’s stock valued at $73,338,000 after buying an additional 1,577,640 shares during the last quarter. Vanguard Group Inc grew its stake in shares of Medpace by 63.6% during the third quarter. Vanguard Group Inc now owns 2,897,702 shares of the company’s stock valued at $173,601,000 after buying an additional 1,126,649 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Medpace by 63.6% during the third quarter. Vanguard Group Inc. now owns 2,897,702 shares of the company’s stock valued at $173,601,000 after buying an additional 1,126,649 shares during the last quarter. Finally, Fuller & Thaler Asset Management Inc. bought a new position in shares of Medpace during the third quarter valued at approximately $37,292,000. 83.00% of the stock is currently owned by hedge funds and other institutional investors.

In other news, CEO August J. Troendle sold 600 shares of the stock in a transaction on Tuesday, January 15th. The stock was sold at an average price of $61.00, for a total transaction of $36,600.00. Following the completion of the sale, the chief executive officer now owns 603,702 shares in the company, valued at approximately $36,825,822. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Medpace Investors, Llc sold 16,582 shares of the stock in a transaction on Thursday, January 17th. The shares were sold at an average price of $61.34, for a total value of $1,017,139.88. Following the sale, the insider now owns 8,150,525 shares of the company’s stock, valued at approximately $499,953,203.50. The disclosure for this sale can be found here. In the last quarter, insiders have sold 660,817 shares of company stock valued at $41,996,365. Company insiders own 29.50% of the company’s stock.

Medpace stock traded up $0.73 during mid-day trading on Friday, reaching $54.20. 1,564 shares of the company were exchanged, compared to its average volume of 774,188. The company has a quick ratio of 0.69, a current ratio of 0.69 and a debt-to-equity ratio of 0.18. The firm has a market cap of $1.91 billion, a P/E ratio of 20.88, a P/E/G ratio of 1.67 and a beta of 1.61. Medpace Holdings Inc has a 12-month low of $33.52 and a 12-month high of $71.66.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, February 25th. The company reported $0.76 earnings per share for the quarter, topping analysts’ consensus estimates of $0.69 by $0.07. The company had revenue of $192.12 million during the quarter, compared to analyst estimates of $184.66 million. Medpace had a return on equity of 17.66% and a net margin of 11.27%. Medpace’s revenue was up 70.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.39 earnings per share. Equities analysts expect that Medpace Holdings Inc will post 2.64 earnings per share for the current year.

Several brokerages recently issued reports on MEDP. BidaskClub cut Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, March 9th. Zacks Investment Research cut Medpace from a “hold” rating to a “sell” rating in a research note on Saturday, March 2nd. Finally, ValuEngine raised Medpace from a “hold” rating to a “buy” rating in a research note on Thursday, January 10th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $48.20.

TRADEMARK VIOLATION NOTICE: This story was originally reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://sportsperspectives.com/2019/03/15/oberweis-asset-management-inc-has-3-55-million-stake-in-medpace-holdings-inc-medp.html.

Medpace Company Profile

Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.

Featured Article: How are institutional investors different from individual investors?

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings Inc (NASDAQ:MEDP).

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.